The Pan-RAS Breakthrough: Doubling Survival Rates in Pancreatic Cancer
A landmark breakthrough: RMC-6236 rewrites the landscape of pancreatic cancer Treatment
On April 13 2026, Revolution Medicines officially announced groundbreaking results of its pivotal Phase III clinical study for daraxonrasib (RMC-6236), a pan-RAS targeted drug. The study, evaluating patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC), successfully met its primary survival endpoint with stellar clinical data: compared to standard chemotherapy, daraxonrasib significantly prolonged the median overall survival (OS) of patients from 6.7 months to 13.2 months, nearly doubling the survival lifespan; the hazard ratio (HR) was 0.40, indicating a substantial 60% reduction in the risk of death.
The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival, Revolution Medicines Official Data[1]
Current Market Size for RAS Inhibitors
With its breakthrough survival benefits, RMC-6236 has become the world's first pan-RAS targeted drug proven to bring significant survival advantages in a Phase III study for pancreatic cancer, achieving a milestone breakthrough for this highly aggressive cancer type and promising to completely rewrite the clinical treatment landscape for advanced pancreatic cancer. On the first trading day following the data release, RevMed's stock price soared by over 40%, with its market value instantly surpassing $29.5 billion (approximately 200 billion RMB). For a pharmaceutical company without any commercialized products on the market, this valuation is nothing short of a miracle, surpassing domestic innovative drug leaders such as Innovent Biologics and Akeso. Boosted by this news, domestic enterprises in the same track also experienced general gains, with the stock prices of Gmax Biopharm (Jinfang Med) and Jacobio surging by 17% and 8% respectively.
|
Drug |
Target |
Company |
Highest Clinical Progress |
Indication |
|
Sotorasib |
KRAS G12C |
Amgen |
Approved for Market |
Locally advanced/metastatic non-small cell lung cancer |
|
Adagrasib |
KRAS G12C |
Mirati Therapeutics (BMS) / Zai Lab |
Approved for Market |
Locally advanced/metastatic non-small cell lung cancer |
|
Daraxonrasib |
Pan-RAS (RAS-ON) |
Revolution Medicines |
Approved for Market |
Locally advanced or metastatic non-small cell lung cancer harboring KRAS G12C mutation |
|
GFH276 |
KRAS G12D |
Gmax Biopharm (Jinfang Med) |
Phase I Clinical |
Advanced solid tumors (colorectal cancer, pancreatic cancer) |
|
ASKC189 |
KRAS G12D/G12V |
Ausper Bio (Ousaikang) / Adcentrx (Anuo Med) |
Phase I Clinical |
Advanced solid tumors (colorectal cancer, pancreatic cancer, non-small cell lung cancer) |
|
RMC-4996 |
Pan-RAS (RAS-ON) |
Revolution Medicines |
Phase I/II Clinical |
Advanced solid tumors (non-small cell lung cancer, colorectal cancer, pancreatic cancer, etc.) |
A Selection of Representative Drugs and Clinical Pipeline Layout in Part of the RAS Targeted Field
RAS Family: From Signal Transduction to Tumorigenesis
The RAS family consists of crucial small GTPase signal transduction proteins in the human body, mainly including three major isoforms: HRAS, KRAS, and NRAS. By cycling between GDP-bound and GTP-bound states, they precisely transmit upstream growth factor signals to regulate processes such as cell proliferation, differentiation, apoptosis, and metabolism.
Abnormal mutations in RAS genes are core drivers for the initiation and progression of various solid tumors. Mutations are mostly concentrated at the G12, G13, and Q61 hotspot sites, causing RAS proteins to lose their GTP hydrolysis activity and remain constitutively active. This drives the abnormal activation of downstream pro-cancer pathways like MAPK and PI3K/AKT, inducing malignant proliferation, invasion, and metastasis of tumor cells[2].
Among these, KRAS mutations possess the strongest oncogenicity and the highest clinical prevalence. They are highly prevalent in pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal cancer, serving as the critical incentive for the high malignancy, rapid progression, and poor prognosis of these tumors[3].
KACTUS KRAS Product Portfolio
At this critical juncture of pan-RAS targeted therapy, KACTUS provides a full series of KRAS target tools, ranging from Monomers to Tetramers, supporting personalized customization to help accelerate your research.
Precisely Matching the R&D Needs of High-Incidence Cancer Types:
- Lung Cancer Direction: Covering G12C (A02:01/A11:01)
- Pancreatic/Colorectal Cancer Direction: Covering G12D / G12V (A02:01/A03:01)
- More mutation combinations support customization
Related Products
Explore our full catalog of KACTUS KRAS-peptide MHC Recombinant Proteins
References
[1] Dbouk M, KatonalBW, Brand RE, et al. The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival. J Clin Oncol. 2022;40:3257-3266. doi: 10.1200/JCO.22.00298.
[2] Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012 May;72(10):2457-2467. doi: 10.1158/0008-5472.can-11-2612. PMID: 22589270; PMCID: PMC3354961.
[3] Liang J, Wu J, Zhang Y, et al. Systematic and precise interventions for KRAS-mutant cancers. Exp Hematol Oncol 15, 33 (2026). https://doi.org/10.1186/s40164-026-00763-7
